Literature DB >> 19696481

Prediction of hemodynamically significant coronary artery disease using troponin I in hemodialysis patients presenting with chest pain: A case-control study.

Olurotimi J Badero1, Moro O Salifu.   

Abstract

OBJECTIVES: Controversy exists regarding utility of cardiac troponin I (cTnI) in predicting significant coronary artery disease (CAD) in hemodialysis (HD) patients with chest pain and no acute ischemia on electrocardiogram (non-ST segment elevation myocardial infarction, non-STEMI). We sought to determine if cTnI elevation predicts significant CAD (>70% stenosis) in these patients.
METHODS: Ninety patients with non-STEMI referred for cardiac catheterization were included, divided equally into HD and non-HD groups.
RESULTS: Mean age and baseline characteristics were not significantly different between groups, except for left ventricular hypertrophy which was higher in HD patients (56 vs. 27%, p = 0.012). Initial cTnI correlated with obstructive CAD and was stratified into <0.3 and >0.3 ng/ml. By logistic regression, cTnI >0.3 ng/ml was not predictive of CAD in HD patients [odds ratio = 0.87 (95% CI 0.19-4.0), p = 0.8], while non-HD patients had an increased risk of CAD if first cTnI was >0.3 ng/ml [odds ratio = 1.461 (95% CI 1.01-2.11), p = 0.04] as expected. Sensitivity, specificity, negative and positive predictive values of cTnI in predicting obstructive CAD were better in non-HD patients.
CONCLUSION: cTnI in these patients had no predictive value for obstructive CAD. This contrasts with the general population, suggesting a higher index of suspicion for high-grade CAD irrespective of cTnI levels in HD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696481     DOI: 10.1159/000235651

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  1 in total

1.  Association between troponin I level and cardiovascular risk factors in asymptomatic hemodialysis patients.

Authors:  Shahram Taheri; Ali Asghar Pilehvarian; Nafiseh Akbari; Samane Musavi; Afsoon Emami Naeini
Journal:  J Res Pharm Pract       Date:  2016 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.